美罗华时代自体造血干细胞移植治疗侵袭性B细胞淋巴瘤的应用.ppt

The incidences of cytogenetic aberrations in MCL with BMI Yi SH，Zou DH，et al. Oncotaget (2015) RR 95% CI P value PFS MIPI 1.6 0.9-3.0 .135 Deletion 13q 1.1 0.5-2.8 .761 Deletions 17p 2.5 1.1-5.9 .039 MYC abnormality 3.1 1.2-7.8 .020 Any cytogenetic aberration 0.9 0.3-3.5 .923 OS Deletions 13q 0.9 0.4-2.3 .829 Deletions 17p 2.4 1.02- 5.8 .045 MYC abnormality 3.21 1.15-8.96 .026 Any cytogenetic aberration 2.5 0.5-12.3 .257 CHOP/CHOP-like ±R .831 0.5-2.5 .831 Biological targeting treatment in MCL: based on potential pathogenetic mechanisms. Published in: Piotr Smolewski; Magdalena Witkowska; T